Does the media refer more to NVO or AZN?

In the previous week, Novo Nordisk A/S had 30 more articles in the media than Astrazeneca. MarketBeat recorded 35 mentions for Novo Nordisk A/S and 5 mentions for Astrazeneca. Novo Nordisk A/S's average media sentiment score of 0.79 beat Astrazeneca's score of 0.32 indicating that Novo Nordisk A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 20 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive Astrazeneca 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Is NVS or NVO more profitable?

Novo Nordisk A/S has a net margin of 37.23% compared to Novartis' net margin of 24.87%. Novo Nordisk A/S's return on equity of 63.31% beat Novartis' return on equity. Company Net Margins Return on Equity Return on Assets Novartis 24.87% 38.82% 15.16% Novo Nordisk A/S 37.23% 63.31% 22.19%

Does the media prefer NVS or NVO?

In the previous week, Novo Nordisk A/S had 33 more articles in the media than Novartis. MarketBeat recorded 35 mentions for Novo Nordisk A/S and 2 mentions for Novartis. Novo Nordisk A/S's average media sentiment score of 0.79 beat Novartis' score of -0.99 indicating that Novo Nordisk A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novartis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative Novo Nordisk A/S 20 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive

Which has higher valuation & earnings, NVO or SNY?

Novo Nordisk A/S has higher earnings, but lower revenue than Sanofi. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novo Nordisk A/S $46.80B 4.35 $15.51B $4.26 10.70 Sanofi $49.35B 2.16 $8.84B $3.58 12.20

Is NVO or SNY more profitable?

Novo Nordisk A/S has a net margin of 37.23% compared to Sanofi's net margin of 16.95%. Novo Nordisk A/S's return on equity of 63.31% beat Sanofi's return on equity. Company Net Margins Return on Equity Return on Assets Novo Nordisk A/S 37.23% 63.31% 22.19% Sanofi 16.95% 13.39% 7.58%

Does the media favor NVO or SNY?

In the previous week, Novo Nordisk A/S had 32 more articles in the media than Sanofi. MarketBeat recorded 35 mentions for Novo Nordisk A/S and 3 mentions for Sanofi. Novo Nordisk A/S's average media sentiment score of 0.79 beat Sanofi's score of 0.61 indicating that Novo Nordisk A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 20 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive Sanofi 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, NVO or GSK?

Novo Nordisk A/S has higher revenue and earnings than GSK. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novo Nordisk A/S $46.80B 4.35 $15.51B $4.26 10.70 GSK $43.07B 2.38 $7.54B $3.85 13.13

Is NVO or GSK more profitable?

Novo Nordisk A/S has a net margin of 37.23% compared to GSK's net margin of 17.82%. Novo Nordisk A/S's return on equity of 63.31% beat GSK's return on equity. Company Net Margins Return on Equity Return on Assets Novo Nordisk A/S 37.23% 63.31% 22.19% GSK 17.82% 44.28% 11.49%

Does the media favor NVO or GSK?

In the previous week, Novo Nordisk A/S had 23 more articles in the media than GSK. MarketBeat recorded 35 mentions for Novo Nordisk A/S and 12 mentions for GSK. Novo Nordisk A/S's average media sentiment score of 0.79 beat GSK's score of 0.57 indicating that Novo Nordisk A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novo Nordisk A/S 20 Very Positive mention(s) 4 Positive mention(s) 7 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive GSK 6 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer TAK or NVO?

Novo Nordisk A/S has a consensus target price of $65.56, indicating a potential upside of 43.86%. Given Novo Nordisk A/S's higher possible upside, analysts clearly believe Novo Nordisk A/S is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Novo Nordisk A/S 1 Sell rating(s) 18 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.13

Novo Nordisk A/S (NVO) Competitors

$45.57 +0.06 (+0.14%)

Closing price 03:59 PM Eastern

Extended Trading

$45.56 -0.01 (-0.03%)

As of 07:59 PM Eastern

Compare

NVO vs. AZN, NVS, SNY, GSK, and TAK

Should you buy Novo Nordisk A/S stock or one of its competitors? MarketBeat compares Novo Nordisk A/S with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Novo Nordisk A/S include Astrazeneca (AZN), Novartis (NVS), Sanofi (SNY), GSK (GSK), and Takeda Pharmaceutical (TAK). These companies are all part of the "pharmaceutical products" industry.

How does Novo Nordisk A/S compare to Astrazeneca?

Novo Nordisk A/S (NYSE:NVO) and Astrazeneca (NYSE:AZN) are both large-cap pharmaceutical products companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

Novo Nordisk A/S currently has a consensus target price of $65.56, indicating a potential upside of 43.86%. Astrazeneca has a consensus target price of $205.33, indicating a potential upside of 10.69%. Given Novo Nordisk A/S's higher possible upside, equities research analysts plainly believe Novo Nordisk A/S is more favorable than Astrazeneca.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	1 Sell rating(s)	18 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13
Astrazeneca	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85

Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.8%. Astrazeneca pays an annual dividend of $4.34 per share and has a dividend yield of 2.3%. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. Astrazeneca pays out 65.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Novo Nordisk A/S has a net margin of 37.23% compared to Astrazeneca's net margin of 17.19%. Novo Nordisk A/S's return on equity of 63.31% beat Astrazeneca's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	37.23%	63.31%	22.19%
Astrazeneca	17.19%	30.86%	12.68%

In the previous week, Novo Nordisk A/S had 30 more articles in the media than Astrazeneca. MarketBeat recorded 35 mentions for Novo Nordisk A/S and 5 mentions for Astrazeneca. Novo Nordisk A/S's average media sentiment score of 0.79 beat Astrazeneca's score of 0.32 indicating that Novo Nordisk A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	20 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive
Astrazeneca	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Novo Nordisk A/S has higher earnings, but lower revenue than Astrazeneca. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Astrazeneca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	4.35	$15.51B	$4.26	10.70
Astrazeneca	$58.74B	4.90	$10.23B	$6.66	27.85

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 20.4% of Astrazeneca shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Novo Nordisk A/S has a beta of 0.77, indicating that its stock price is 23% less volatile than the broader market. Comparatively, Astrazeneca has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market.

Summary

Novo Nordisk A/S beats Astrazeneca on 11 of the 18 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Novartis?

Novartis (NYSE:NVS) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

Novartis has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market.

13.1% of Novartis shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 0.0% of Novartis shares are owned by insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Novartis pays an annual dividend of $3.08 per share and has a dividend yield of 2.1%. Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.8%. Novartis pays out 44.1% of its earnings in the form of a dividend. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Novo Nordisk A/S has lower revenue, but higher earnings than Novartis. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Novartis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novartis	$54.53B	5.26	$13.98B	$6.98	21.52
Novo Nordisk A/S	$46.80B	4.35	$15.51B	$4.26	10.70

Novo Nordisk A/S has a net margin of 37.23% compared to Novartis' net margin of 24.87%. Novo Nordisk A/S's return on equity of 63.31% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novartis	24.87%	38.82%	15.16%
Novo Nordisk A/S	37.23%	63.31%	22.19%

Novartis presently has a consensus target price of $141.20, indicating a potential downside of 6.01%. Novo Nordisk A/S has a consensus target price of $65.56, indicating a potential upside of 43.86%. Given Novo Nordisk A/S's higher probable upside, analysts plainly believe Novo Nordisk A/S is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novartis	2 Sell rating(s)	7 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.31
Novo Nordisk A/S	1 Sell rating(s)	18 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13

In the previous week, Novo Nordisk A/S had 33 more articles in the media than Novartis. MarketBeat recorded 35 mentions for Novo Nordisk A/S and 2 mentions for Novartis. Novo Nordisk A/S's average media sentiment score of 0.79 beat Novartis' score of -0.99 indicating that Novo Nordisk A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novartis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative
Novo Nordisk A/S	20 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Novo Nordisk A/S beats Novartis on 11 of the 18 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Sanofi?

Novo Nordisk A/S (NYSE:NVO) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment.

Novo Nordisk A/S has a net margin of 37.23% compared to Sanofi's net margin of 16.95%. Novo Nordisk A/S's return on equity of 63.31% beat Sanofi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	37.23%	63.31%	22.19%
Sanofi	16.95%	13.39%	7.58%

In the previous week, Novo Nordisk A/S had 32 more articles in the media than Sanofi. MarketBeat recorded 35 mentions for Novo Nordisk A/S and 3 mentions for Sanofi. Novo Nordisk A/S's average media sentiment score of 0.79 beat Sanofi's score of 0.61 indicating that Novo Nordisk A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	20 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive
Sanofi	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novo Nordisk A/S currently has a consensus target price of $65.56, suggesting a potential upside of 43.86%. Sanofi has a consensus target price of $51.00, suggesting a potential upside of 16.78%. Given Novo Nordisk A/S's higher probable upside, research analysts clearly believe Novo Nordisk A/S is more favorable than Sanofi.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	1 Sell rating(s)	18 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13
Sanofi	0 Sell rating(s)	10 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	2.47

Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.8%. Sanofi pays an annual dividend of $1.76 per share and has a dividend yield of 4.0%. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. Sanofi pays out 49.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 14.0% of Sanofi shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by company insiders. Comparatively, 1.0% of Sanofi shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Novo Nordisk A/S has higher earnings, but lower revenue than Sanofi. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	4.35	$15.51B	$4.26	10.70
Sanofi	$49.35B	2.16	$8.84B	$3.58	12.20

Novo Nordisk A/S has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market. Comparatively, Sanofi has a beta of 0.35, meaning that its share price is 65% less volatile than the broader market.

Summary

Novo Nordisk A/S beats Sanofi on 12 of the 19 factors compared between the two stocks.

How does Novo Nordisk A/S compare to GSK?

Novo Nordisk A/S (NYSE:NVO) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

Novo Nordisk A/S has higher revenue and earnings than GSK. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$46.80B	4.35	$15.51B	$4.26	10.70
GSK	$43.07B	2.38	$7.54B	$3.85	13.13

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 15.7% of GSK shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by company insiders. Comparatively, 10.0% of GSK shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Novo Nordisk A/S has a net margin of 37.23% compared to GSK's net margin of 17.82%. Novo Nordisk A/S's return on equity of 63.31% beat GSK's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	37.23%	63.31%	22.19%
GSK	17.82%	44.28%	11.49%

Novo Nordisk A/S has a beta of 0.77, meaning that its stock price is 23% less volatile than the broader market. Comparatively, GSK has a beta of 0.38, meaning that its stock price is 62% less volatile than the broader market.

In the previous week, Novo Nordisk A/S had 23 more articles in the media than GSK. MarketBeat recorded 35 mentions for Novo Nordisk A/S and 12 mentions for GSK. Novo Nordisk A/S's average media sentiment score of 0.79 beat GSK's score of 0.57 indicating that Novo Nordisk A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	20 Very Positive mention(s)	4 Positive mention(s)	7 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Positive
GSK	6 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novo Nordisk A/S presently has a consensus target price of $65.56, indicating a potential upside of 43.86%. GSK has a consensus target price of $53.00, indicating a potential upside of 4.81%. Given Novo Nordisk A/S's stronger consensus rating and higher possible upside, analysts plainly believe Novo Nordisk A/S is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	1 Sell rating(s)	18 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13
GSK	3 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.90

Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.8%. GSK pays an annual dividend of $1.81 per share and has a dividend yield of 3.6%. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. GSK pays out 47.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Summary

Novo Nordisk A/S beats GSK on 15 of the 18 factors compared between the two stocks.

How does Novo Nordisk A/S compare to Takeda Pharmaceutical?

Takeda Pharmaceutical (NYSE:TAK) and Novo Nordisk A/S (NYSE:NVO) are both large-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

Takeda Pharmaceutical has a beta of -0.06, suggesting that its share price is 106% less volatile than the broader market. Comparatively, Novo Nordisk A/S has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

Novo Nordisk A/S has a net margin of 37.23% compared to Takeda Pharmaceutical's net margin of 4.31%. Novo Nordisk A/S's return on equity of 63.31% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Takeda Pharmaceutical	4.31%	11.07%	5.49%
Novo Nordisk A/S	37.23%	63.31%	22.19%

In the previous week, Novo Nordisk A/S had 35 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 35 mentions for Novo Nordisk A/S and 0 mentions for Takeda Pharmaceutical. Novo Nordisk A/S's average media sentiment score of 0.79 beat Takeda Pharmaceutical's score of -0.08 indicating that Novo Nordisk A/S is being referred to more favorably in the news media.

Company	Overall Sentiment
Takeda Pharmaceutical	Neutral
Novo Nordisk A/S	Positive

Takeda Pharmaceutical pays an annual dividend of $0.50 per share and has a dividend yield of 3.1%. Novo Nordisk A/S pays an annual dividend of $1.75 per share and has a dividend yield of 3.8%. Takeda Pharmaceutical pays out 128.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Novo Nordisk A/S pays out 41.1% of its earnings in the form of a dividend. Novo Nordisk A/S is clearly the better dividend stock, given its higher yield and lower payout ratio.

Novo Nordisk A/S has a consensus target price of $65.56, indicating a potential upside of 43.86%. Given Novo Nordisk A/S's higher possible upside, analysts clearly believe Novo Nordisk A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50
Novo Nordisk A/S	1 Sell rating(s)	18 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13

Novo Nordisk A/S has higher revenue and earnings than Takeda Pharmaceutical. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Takeda Pharmaceutical	$28.32B	1.79	$1.27B	$0.39	40.94
Novo Nordisk A/S	$46.80B	4.35	$15.51B	$4.26	10.70

9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 11.5% of Novo Nordisk A/S shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by insiders. Comparatively, 0.1% of Novo Nordisk A/S shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Novo Nordisk A/S beats Takeda Pharmaceutical on 16 of the 18 factors compared between the two stocks.

Get Novo Nordisk A/S News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NVO vs. The Competition

Export

Metric	Novo Nordisk A/S	Large Cap Pharma Industry	Medical Sector	NYSE Exchange
Market Cap	$203.20B	$311.49B	$6.49B	$23.18B
Dividend Yield	3.84%	2.75%	2.69%	4.06%
P/E Ratio	10.70	27.39	18.17	27.83
Price / Sales	4.35	5.06	561.98	24.71
Price / Cash	9.71	13.28	43.65	25.09
Price / Book	6.40	7.30	10.60	4.79
Net Income	$15.51B	$11.61B	$3.56B	$1.07B
7 Day Performance	1.48%	-1.32%	2.97%	1.16%
1 Month Performance	13.14%	4.78%	6.25%	2.87%
1 Year Performance	-34.39%	23.54%	36.72%	27.33%

Novo Nordisk A/S Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NVO Novo Nordisk A/S	4.372 of 5 stars	$45.57 +0.1%	$65.56 +43.9%	-33.7%	$203.20B	$46.80B	10.70	69,505	Trending News
AZN Astrazeneca	3.6117 of 5 stars	$187.25 +1.4%	$205.33 +9.7%	+31.9%	$290.49B	$58.74B	28.12	96,100
NVS Novartis	2.6487 of 5 stars	$151.14 +0.5%	$141.20 -6.6%	+35.3%	$288.53B	$56.58B	21.66	75,267
SNY Sanofi	4.4648 of 5 stars	$44.63 +2.5%	$51.00 +14.3%	-14.8%	$108.85B	$49.35B	12.47	74,846	Positive News
GSK GSK	2.6225 of 5 stars	$50.91 -0.3%	$53.00 +4.1%	+30.7%	$103.40B	$32.78B	13.24	66,841	Trending News Dividend Cut

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:NVO) was last updated on 5/29/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novo Nordisk A/S (NVO) Competitors

NVO vs. AZN, NVS, SNY, GSK, and TAK

How does Novo Nordisk A/S compare to Astrazeneca?

Summary

How does Novo Nordisk A/S compare to Novartis?

Summary

How does Novo Nordisk A/S compare to Sanofi?

Summary

How does Novo Nordisk A/S compare to GSK?

Summary

How does Novo Nordisk A/S compare to Takeda Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVO vs. The Competition

Novo Nordisk A/S Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novo Nordisk A/S (NVO) Competitors

NVO vs. AZN, NVS, SNY, GSK, and TAK

How does Novo Nordisk A/S compare to Astrazeneca?

Do analysts recommend NVO or AZN?

Is NVO or AZN a better dividend stock?

Is NVO or AZN more profitable?

Does the media refer more to NVO or AZN?

Which has preferable valuation and earnings, NVO or AZN?

Do institutionals & insiders have more ownership in NVO or AZN?

Which has more risk and volatility, NVO or AZN?

Summary

How does Novo Nordisk A/S compare to Novartis?

Which has more risk & volatility, NVS or NVO?

Do insiders and institutionals hold more shares of NVS or NVO?

Is NVS or NVO a better dividend stock?

Which has higher valuation and earnings, NVS or NVO?

Is NVS or NVO more profitable?

Do analysts prefer NVS or NVO?

Does the media prefer NVS or NVO?

Summary

How does Novo Nordisk A/S compare to Sanofi?

Is NVO or SNY more profitable?

Does the media favor NVO or SNY?

Do analysts prefer NVO or SNY?

Is NVO or SNY a better dividend stock?

Do insiders and institutionals hold more shares of NVO or SNY?

Which has higher valuation & earnings, NVO or SNY?

Which has more volatility and risk, NVO or SNY?

Summary

How does Novo Nordisk A/S compare to GSK?

Which has stronger earnings & valuation, NVO or GSK?

Do insiders & institutionals believe in NVO or GSK?

Is NVO or GSK more profitable?

Which has more volatility & risk, NVO or GSK?

Does the media favor NVO or GSK?

Do analysts prefer NVO or GSK?

Is NVO or GSK a better dividend stock?

Summary

How does Novo Nordisk A/S compare to Takeda Pharmaceutical?

Which has more volatility & risk, TAK or NVO?

Is TAK or NVO more profitable?

Does the media refer more to TAK or NVO?

Is TAK or NVO a better dividend stock?

Do analysts prefer TAK or NVO?

Which has better earnings & valuation, TAK or NVO?

Do institutionals and insiders believe in TAK or NVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NVO vs. The Competition

Novo Nordisk A/S Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools